Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/dc06-0546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data.
Circ Genom Precis Med
January 2025
Mary and Steve Wen Cardiovascular Division, Department of Medicine, University of California, Los Angeles. (W.F., N.D.W.).
Background: Lp(a; Lipoprotein[a]) is a predictor of atherosclerotic cardiovascular disease (ASCVD); however, there are few algorithms incorporating Lp(a), especially from real-world settings. We developed an electronic health record (EHR)-based risk prediction algorithm including Lp(a).
Methods: Utilizing a large EHR database, we categorized Lp(a) cut points at 25, 50, and 75 mg/dL and constructed 10-year ASCVD risk prediction models incorporating Lp(a), with external validation in a pooled cohort of 4 US prospective studies.
The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease.
Sci Rep
January 2025
Department of Cardiology, Taian 88 Hospital, China RongTong Medical Healthcare Group Co.Ltd, Taian, 271000, China.
Lipoprotein(a) [Lp(a)] is a lipoprotein with potent atherogenic and thrombogenic potential. Its role in patients with acute coronary syndrome (ACS) combined with three-vessel disease (TVD) remains unclear. This study aimed to investigate the correlation between Lp(a) levels and the occurrence of major adverse cardiovascular events (MACE) in patients with ACS combined with TVD.
View Article and Find Full Text PDFPretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma.
Int J Gen Med
December 2024
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Article Synopsis
- This study explores the relationship between pretreatment serum lipoprotein(a) [Lp(a)] levels and EGFR gene mutations in patients with advanced lung adenocarcinoma undergoing treatment with EGFR-TKIs.
- The research evaluated 338 patients and concluded that a higher Lp(a) level (above 20.48 mg/L) is linked to a lower rate of EGFR mutations (48.0% vs 65.5%).
- The findings also indicate that higher Lp(a) levels are associated with longer progression-free survival (16.1 months vs 9.6 months), suggesting it is a significant independent predictor for both EGFR mutations and PFS.
Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy.
Anticancer Res
January 2025
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background/aim: Lipoprotein(a) (Lp(a)) is a complex protein involved in the transport of insoluble lipids in plasma. Its expression is predominantly genetically determined, with 70% to over 90% influenced by the number of Kringle IV type 2 domains. This study investigated the association between preoperative serum Lp(a) level and development of post-pancreatectomy nonalcoholic fatty liver disease (NAFLD) in patients who underwent pancreatectomy.
View Article and Find Full Text PDFCoronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein(a) Levels in Patients With Acute Coronary Syndrome.
Catheter Cardiovasc Interv
December 2024
Cardiothoracovascular Department, Division of Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy.
Background: Lipoprotein(a) [Lp(a)] is associated with increased cardiovascular risk, but its influence on plaque characteristics at optical coherence tomography (OCT) evaluation is not fully understood.
Aims: This study seeks to explore the impact of Lp(a) levels on plaque morphology as assessed by OCT in a very high-risk subset of patients.
Methods: Consecutive patients admitted for acute coronary syndrome (ACS) and undergoing OCT-guided percutaneous coronary intervention (PCI) at a large tertiary care center between 2019 and 2022 were deemed eligible for the current analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!